China Feihe Limited
CFEIY
Other OTC4.39
USD
- -
- -
ISIN
US16892L1008
CUSIP
16892L100
Return %
Stock
S&P500
1Y
-24.70
18.86
3Y
-23.65
64.57
5Y
-80.65
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Youbin Leng
- Full Time Employees
- 9,480
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- Star City International Building Beijing HL People's Republic of China 100016
- IPO Date
- Jan 15, 2020
- Website
- feihe.com
- Similar Companies
- Business
- China Feihe Limited China Feihe Limited (Ticker: CFEIY), an investment holding company incorporated in the Cayman Islands, engages in the production and sale of dairy products, raw milk, and nutritional supplements primarily in Mainland China, with operations extending to Canada and the United States. The company offers a diversified portfolio of infant milk formula products designed to mimic the composition of Chinese breast milk, including super-premium brands such as Astrobaby, Astrobaby A2, Super-Premium Organic Zhenzhi, Super-Zhuorui, Organic Chunrui, and premium lines like Zhenai Beihu, OPremium Zhenai Feifan, Xingjie Youhu, Feifan, Miao Shu Huan, and Zhouran; adult milk powders; liquid milk products; soybean powder; rice powder supplements; and health care products including vitamins, minerals, herbs, and nutritional supplements retailed through Vitamin World USA. Founded in 1962 and headquartered at Star City International Building in Beijing, China, the company distributes its products via an extensive nationwide network of over 2,800 offline distributors covering more than 80,000 retail points including maternity stores, supermarkets, and hypermarkets, as well as e-commerce platforms, its own website, and mobile applications, with infant formula comprising approximately 90% of sales. China Feihe Limited maintains 11 production facilities with a total annual capacity exceeding 363,000 tonnes, including recent expansions in liquid milk production; it obtained its first infant formula production license in Canada in April 2024 and continues share repurchases, such as 20 million shares in November 2025 and ongoing subscriptions to low-risk financial products from SPD Bank totaling RMB2.2 billion as of October 2025 to optimize idle funds.
China Feihe (OTCMKTS:CFEIY) Trading Down 9.8% – What’s Next?
China Feihe downgraded to Neutral from Buy at Goldman Sachs
China Feihe downgraded to Neutral from Buy at Goldman Sachs
China Feihe downgraded to Neutral from Buy at Goldman Sachs
The 3 Most Undervalued Stocks Under $1 to Buy Now: August 2023